Troluce Capital Advisors LLC Buys New Shares in TScan Therapeutics, Inc. (NASDAQ:TCRX)

Troluce Capital Advisors LLC bought a new position in shares of TScan Therapeutics, Inc. (NASDAQ:TCRX) during the 2nd quarter, Holdings Channel.com reports. The firm bought 92,832 shares of the company’s stock, valued at approximately $543,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its holdings in shares of TScan Therapeutics by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 1,808,152 shares of the company’s stock worth $14,357,000 after acquiring an additional 20,000 shares during the period. Great Point Partners LLC purchased a new stake in TScan Therapeutics in the second quarter valued at approximately $5,504,000. Marshall Wace LLP raised its stake in TScan Therapeutics by 60.8% during the second quarter. Marshall Wace LLP now owns 307,487 shares of the company’s stock worth $1,799,000 after purchasing an additional 116,316 shares during the period. Tocqueville Asset Management L.P. purchased a new position in TScan Therapeutics during the first quarter worth approximately $1,685,000. Finally, Bank of Montreal Can acquired a new position in shares of TScan Therapeutics in the 2nd quarter valued at $749,000. 82.83% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TCRX has been the subject of a number of research analyst reports. Needham & Company LLC restated a “buy” rating and set a $11.00 price objective on shares of TScan Therapeutics in a report on Monday, August 12th. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of TScan Therapeutics in a research note on Tuesday, August 13th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $10.00 price objective on shares of TScan Therapeutics in a research note on Monday, August 12th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, TScan Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $12.00.

TScan Therapeutics Stock Performance

NASDAQ:TCRX opened at $5.10 on Wednesday. The firm’s fifty day simple moving average is $6.05 and its 200 day simple moving average is $7.04. The company has a current ratio of 7.77, a quick ratio of 7.77 and a debt-to-equity ratio of 0.08. TScan Therapeutics, Inc. has a twelve month low of $2.43 and a twelve month high of $9.69. The firm has a market capitalization of $270.15 million, a price-to-earnings ratio of -3.98 and a beta of 0.79.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.02. TScan Therapeutics had a negative return on equity of 59.83% and a negative net margin of 855.84%. The company had revenue of $0.54 million for the quarter, compared to analysts’ expectations of $1.55 million. As a group, equities research analysts expect that TScan Therapeutics, Inc. will post -1.36 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Barbara Klencke acquired 5,000 shares of the company’s stock in a transaction dated Monday, September 23rd. The shares were bought at an average price of $5.29 per share, for a total transaction of $26,450.00. Following the completion of the purchase, the director now directly owns 45,000 shares of the company’s stock, valued at approximately $238,050. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, Director Barbara Klencke acquired 5,000 shares of the firm’s stock in a transaction on Monday, September 23rd. The stock was bought at an average cost of $5.29 per share, with a total value of $26,450.00. Following the transaction, the director now directly owns 45,000 shares in the company, valued at approximately $238,050. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Zoran Zdraveski sold 164,686 shares of TScan Therapeutics stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $5.78, for a total value of $951,885.08. Following the sale, the insider now directly owns 4,716 shares in the company, valued at $27,258.48. The disclosure for this sale can be found here. Insiders purchased a total of 15,000 shares of company stock worth $82,550 in the last 90 days. 2.76% of the stock is owned by company insiders.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.